Showing 71-80 of 904 results for "".
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Gui
- LEO Pharma Taps Jörg Möller as EVP, Global Research and Developmenthttps://practicaldermatology.com/news/leo-pharma-taps-jorg-moller-as-evp-global-research-and-development/2460636/Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pha
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- New “Sonoillumination” Waveguide Device Set to Improve Laser Surgeryhttps://practicaldermatology.com/news/new-sonoillumination-waveguide-device-set-to-improve-laser-surgery/2458221/One of the biggest issues with the lasers used to treat benign vascular birthmarks, port-wine stains and for tattoo removal is making sure the laser light, which is held at a distance from the skin, is perfectly and selectively absorbed by only the targeted birthmark or tattoo. Paul J.D.
What You Missed at San Diego Dermatology Symposium
https://practicaldermatology.com/topics/psoriasis/what-you-missed-at-san-diego-dermatology-symposium/19884/Jashin Wu, MD, founder of San Diego Dermatology Symposium, gives an overview of the 2020 meeting, which went virtual.Heart of the Matter: Effects of Psoriasis Treatment on CV Risks
https://practicaldermatology.com/topics/psoriasis/heart-of-the-matter-effects-of-psoriasis-treatment-on-cv-risks/18747/By Jashin Wu, MD and Seemal R. Desai, MDThere's growing evidence that treatment of psoriasis reduces the risk of CV events, but it's not clear whether this potential benefit should influence treatment decisions. Patient screening and counseling remain important, Dr. Wu says.Psoriasis and Inflammatory Disease Management Today
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-inflammatory-disease-management-today/19885/COVID-19 can have implications for psoriasis management. Jashin Wu, MD, founder of San Diego Dermatology Symposium, provides guidance on management and introduces the Inaugural Symposium for Inflammatory Skin Disease, coming virtually in April.The Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availExploring the Complexities of Psoriasis
https://practicaldermatology.com/topics/psoriasis/exploring-the-complexities-of-psoriasis/18553/Biologic therapies developed over the last decade or more to treat psoriasis may do more than clear the skin. Researchers are investigating the effects of treatment on comorbid risks, and comparing treatment with older interventions. Jashin Wu, MD explains.Papa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arou